Wird geladen...
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
We screened TP53 mutations in 168 MDS patients who were treated with HMA and evaluated predictive and prognostic value of TP53 mutations. Overall response to HMA was not different based on TP53 mutation status (45% vs. 32% in TP53-mutated and wild type [WT], respectively, P = 0.13). However, respons...
Gespeichert in:
| Veröffentlicht in: | Oncotarget |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Impact Journals LLC
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4924706/ https://ncbi.nlm.nih.gov/pubmed/26871476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7290 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|